| Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. | |
| | |
MedLine Citation:
|
PMID: 19147689 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Numerous clinical studies have demonstrated the therapeutic benefit of trastuzumab in women with breast cancer. However, a small but not insignificant proportion of patients have experienced trastuzumab-associated cardiotoxicity during these trials. This phenomenon is generally characterized by an asymptomatic reduction in left ventricular ejection fraction (LVEF) or, less often, congestive heart failure (CHF). Concomitant anthracycline therapy significantly increases the risk for cardiotoxicity during trastuzumab treatment, and such regimens are therefore not recommended. The cardiac dysfunction associated with trastuzumab is most often reversible upon discontinuation of treatment and initiation of standard medical therapy for CHF. Prior to treatment initiation, a risk-benefit analysis should be performed for each individual patient, including a thorough assessment of potential risk factors and cardiac function. Cardiac monitoring should be continued throughout trastuzumab therapy and the follow-up period, because early recognition of trastuzumab-associated cardiac dysfunction can allow effective medical intervention. Following the occurrence of asymptomatic LVEF reduction or CHF and appropriate medical intervention, reintroduction of trastuzumab may be considered in patients following resolution of normal cardiac function, or in those for whom the benefit of antitumor therapy outweighs the risk for CHF. |
| | |
Authors:
|
Miguel Martín; Francisco J Esteva; Emilio Alba; Bijoy Khandheria; Leopoldo Pérez-Isla; José Angel García-Sáenz; Antonia Márquez; Partho Sengupta; José Zamorano |
Related Documents
:
|
22427939 - The homeostatic chemokine ccl21 predicts mortality and may play a pathogenic role in he... 9072289 - Pathophysiology of plaque rupture and the concept of plaque stabilization. 1936019 - Intra-operative transoesophageal echocardiography after mitral repair--specific conditi... |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-01-15 |
Journal Detail:
|
Title: The oncologist Volume: 14 ISSN: 1549-490X ISO Abbreviation: Oncologist Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-02-02 Completed Date: 2009-06-25 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 9607837 Medline TA: Oncologist Country: United States |
Other Details:
|
Languages: eng Pagination: 1-11 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain. mmartin@geicam.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
administration & dosage*,
adverse effects* Antibodies, Monoclonal, Humanized Antineoplastic Agents / administration & dosage*, adverse effects* Breast Neoplasms / drug therapy* Female Heart Diseases / chemically induced* Humans |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; P188ANX8CK/trastuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Five strategies for accelerating the war on cancer in an era of budget deficits.
Next Document: Commentary: Disclosure in oncology -- to whom does the truth belong?